Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board.

GlobeNewsWire • Feb 23, 2026

Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026

WATERTOWN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), announced that it will host a virtual key opinion leader (KOL) event and TX2100 discussion on Tuesday, February 24, 2026 from 11:00 a.m. to 12:30 p.m. ET.

GlobeNewsWire • Feb 11, 2026

Tectonic: Strong Buy On Positive Phase 1b TX45 Data And 2026 Inflection Point

Tectonic Therapeutic, Inc. achieved positive results from Part B of the phase 1b study targeting pulmonary hypertension in heart failure with reduced ejection fraction (PH-HFrEF) patients. TECX is targeting CpcPH patients with PVR >3 in the ongoing phase 2 APEX study of PH-HFpEF, with topline data expected in 2026 and expansion into PH-ILD planned then also. TECX holds $268.4 million in cash, sufficient to fund operations into Q4 2028 and support multiple clinical milestones, including several catalysts.

Seeking Alpha • Nov 17, 2025

Tectonic Therapeutic, Inc. (TECX) Discusses Positive Topline Results From Phase Ib Part B Trial of TX45 in PH-HFrEF Patients Transcript

Tectonic Therapeutic, Inc. ( TECX ) Discusses Positive Topline Results From Phase Ib Part B Trial of TX45 in PH-HFrEF Patients October 29, 2025 4:30 PM EDT Company Participants Alise Reicin - President, CEO, Secretary & Director Marcella Ruddy - Chief Medical Officer Conference Call Participants Frances Dovell - TD Cowen, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division David Risinger - Leerink Partners LLC, Research Division Uy Ear - Mizuho Securities USA LLC, Research Division Cory Jubinville - LifeSci Capital, LLC, Research Division Alexander Nackenoff - Truist Securities, Inc., Research Division Martin Auster - Raymond James & Associates, Inc., Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Presentation Operator Good day, and welcome to the TX45 Phase Ib Part B PH-HFrEF data conference call. [Operator Instructions] As a reminder, this call may be recorded.

Seeking Alpha • Oct 31, 2025

Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF

WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive topline results from the Phase 1b Part B acute hemodynamic clinical trial of TX45, a long-acting, Fc-relaxin fusion protein, in patients with Group 2 PH‑HFrEF. The topline data showed that a single intravenous dose of TX45 was well tolerated in this patient population and resulted in meaningful improvements in both left heart function and pulmonary hemodynamics.

GlobeNewsWire • Oct 29, 2025

Tectonic Therapeutic to Participate in September Investor Conferences

WATERTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in three upcoming investor conferences taking place in September 2025.

GlobeNewsWire • Aug 28, 2025

Tectonic (TECX) Q2 R&D Soars 142%

Tectonic Therapeutic (TECX -5.35%), a biotechnology company advancing a new generation of biologic medicines for hard-to-treat diseases, reported its second quarter 2025 results on August 7, 2025. The headline news was a net loss (GAAP) of $20.0 million in Q2 2025, with a loss per share of $(1.07) (GAAP), wider than analysts' expectations of $(0.98) (GAAP).

The Motley Fool • Aug 8, 2025

Tectonic Therapeutic Joins Russell 3000® Index

WATERTOWN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that it has been added to the broad-market Russell 3000® Index. Tectonic's addition follows the conclusion of the 2025 Russell US Indexes annual reconstitution and is effective after the open of US equity markets on Monday, June 30, 2025.

GlobeNewsWire • Jun 30, 2025

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025

WATERTOWN, Mass., May 17, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) today announced the complete results from Part A of the Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), which are being presented in a late-breaking, oral session at the European Society of Cardiology (ESC) Heart Failure 2025 Congress being held in Belgrade, Serbia. The results include the full cohort of 19 patients in Part A of the Phase 1b trial of TX45, Tectonic's lead asset and a long-acting relaxin therapy. Interim data for 16 patients in the Phase 1b trial was previously reported in a press release on January 30, 2025.

GlobeNewsWire • May 17, 2025

Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High?

The consensus price target hints at a 258.5% upside potential for Tectonic Therapeutic, Inc. (TECX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • May 13, 2025